KUALA LUMPUR: Medi Lifestyle Ltd has announced a collaboration between its indirect wholly-owned subsidiaries, HealthPro Pharma Pte Ltd (HPP) and Healthpro Marketing Sdn Bhd (HPM), with FIOR Bioscience, LLC and Shine Bioscience, LLC.
“We aim to import and distribute FDA-registered stem cell therapy products and lead localised research and development efforts. By driving innovation and maintaining the highest safety and ethical standards, we dedicate ourselves to our patients' well-being and satisfaction,” Medi Lifestyle executive director and chief executive officer Datuk Ken Low said in a statement.
Medi Lifestyle said this partnership not only speeds up access to advanced stem cell therapy products but also ignites a healthcare revolution, placing regenerative medicine at the forefront of modern treatment throughout Asia.
The collaboration will blend the distinct and complementary strengths of HPP, HPM, SBS, and Fior Bioscience, united by a shared vision of improving patient outcomes and breaking new ground in medical innovation.
Fior Bioscience, with over a decade and a half of dedicated experience, stands as a perfect alignment to Medi Lifestyle's steadfast commitment to elevating healthcare standards through quality, innovation, and ethical practices.
Mr. David Kasteler, Managing Director of Shine Bioscience, added, “This collaboration signifies a milestone in making stem cell therapies accessible and effective in Asia. Together with Fior Bioscience's pioneering research and the patient-centric approach of Healthpro Pharma and Healthpro Marketing, we're committed to transforming healthcare across the region.”
